@article{oai:soar-ir.repo.nii.ac.jp:00003817,
 author = {Tsukahara,  Tamotsu and Hanazawa,  Shuwa and Kobayashi,  Tetsuyuki and Iwamoto,  Yoshiki and Murakami-Murofushi,  Kimiko},
 issue = {3-4},
 journal = {PROSTAGLANDINS & OTHER LIPID MEDIATORS},
 month = {Nov},
 note = {Cyclic phosphatidic acid (CPA) a structural analog of lysophosphatidic acid (LPA) is one of the simplest phospholipids found in every cell type cPA is a specific high-affinity antagonist of peroxisome proliferator-activated receptor gamma (PPAR gamma) however the molecular mechanism by which cPA inhibits cellular proliferation remains to be clarified In this study we found that inhibition of PPAR gamma prevents proliferation of human colon cancer HT-29 cells CPA suppressed cell growth and this effect was reversed by the addition of a PPAR gamma agonist These results indicate that the physiological effects of cPA are partly due to PPAR gamma inhibition Our results identify PPAR gamma as a molecular mediator of CPA activity in HT-29 cells and suggest that cPA and the PPAR gamma pathway might be therapeutic targets in the treatment of colon cancer, Article, PROSTAGLANDINS & OTHER LIPID MEDIATORS. 93(3-4):126-133 (2010)},
 pages = {126--133},
 title = {Cyclic phosphatidic acid decreases proliferation and survival of colon cancer cells by inhibiting peroxisome proliferator-activated receptor gamma},
 volume = {93},
 year = {2010}
}